97 Results

People

  1. Hellmann
    Hellmann
  2. Rosenberg
    Rosenberg
  3. Rekhtman
    Rekhtman
  4. Rizvi
    Rizvi
  5. Funt
    Funt
  6. Travis
    Travis
  7. Chaft
    Chaft
  8. Chen
    Chen
  9. D'Angelo
    D'Angelo
  10. Iyer
    Iyer

Groups

  1. Department of Medicine (63)
  2. Solid Tumor Oncology Division (56)
  3. Thoracic Oncology (21)
  4. Department of Pathology and Laboratory Medicine (20)
  5. GSK Faculty (16)
  6. Hematologic Malignancies, Division of (16)
  7. Weinberg Fellows (14)
  8. Sloan Kettering Institute Postdocs (13)
  9. Genitourinary Oncology Service (12)
  10. Gastrointestinal Oncology Service (11)
  1. "pd-l1"
Formats
  1. Journal Article (67)
  2. Meeting Abstract (13)
  3. Review (13)
  4. Book Section (2)
  5. Editorial (1)
  6. Guidelines (1)
Groups
  1. Department of Medicine (63)
  2. Solid Tumor Oncology Division (56)
  3. Thoracic Oncology (21)
  4. Department of Pathology and Laboratory Medicine (20)
  5. GSK Faculty (16)
  6. Hematologic Malignancies, Division of (16)

More Groups

People
  1. Matthew Hellmann (10)
  2. Jamie Chaft (6)
  3. Jonathan Rosenberg (6)
  4. Naiyer Rizvi (5)
  5. Natasha Rekhtman (5)
  6. Geoffrey Ku (4)

More People

Years
  1. 2025 (1)
  2. 2024 (4)
  3. 2023 (6)
  4. 2022 (8)
  5. 2021 (12)
  6. 2020 (11)

More Years

Publications
  1. Journal of Thoracic Oncology (16)
  2. Annals of Oncology (9)
  3. Journal for ImmunoTherapy of Cancer (4)
  4. Current Oncology Reports (3)
  5. Future Oncology (3)
  6. Modern Pathology (3)

More Publications

Publishers
  1. Elsevier Inc. (25)
  2. Oxford University Press (11)
  3. Biomed Central Ltd (7)
  4. Springer (6)
  5. Future Medicine (5)
  6. Lippincott Williams & Wilkins (5)

More Publishers

Results (97)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • First-in-human study of FAZ053, an anti-programmed death-ligand 1 (anti-PD-L1) monoclonal antibody, alone and in combination with spartalizumab, in patients with advanced malignancies
    Journal Article

    Janku, F.; Tan, D. S. P.; Martin-Liberal, J.; Takahashi, S.; Geva, R.; Gucalp, A.; Razak, A.; Kan, R.; Reiners, R.; Mataraza, J.; more...
    ESMO Open (2025)

    Fulltext@MSK | Save
  • Gene and protein expression of MAGE and associated immune landscape elements in non-small-cell lung carcinoma and urothelial carcinomas
    Journal Article

    Faiena, I.; Adhikary, S.; Schweitzer, C.; Astrow, S. H.; Grogan, T.; Funt, S. A.; Bot, A.; Dorff, T.; Rosenberg, J. E.; Elashoff, D. A.; more...
    Journal of Immunotherapy (2024)

    Fulltext@MSK | Save
  • Intrapatient variation in PD-L1 expression and tumor mutational burden and the impact on outcomes to immune checkpoint inhibitor therapy in patients with non-small-cell lung cancer
    Journal Article

    Di Federico, A.; Alden, S. L.; Smithy, J. W.; Ricciuti, B.; Alessi, J. V.; Wang, X.; Pecci, F.; Lamberti, G.; Gandhi, M. M.; Vaz, V. R.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Three-year overall survival outcomes and correlative analyses in patients with NSCLC and high (50%–89%) versus very high (≥90%) programmed death-ligand 1 expression treated with first-line pembrolizumab or cemiplimab
    Journal Article

    Ricciuti, B.; Elkrief, A.; Lin, J.; Zhang, J.; Alessi, J. V.; Lamberti, G.; Gandhi, M.; Di Federico, A.; Pecci, F.; Wang, X.; more...
    JTO Clinical and Research Reports (2024)

    Fulltext@MSK | Save
  • Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: Analyses of the CASPIAN phase 3 study
    Journal Article

    Xie, M.; Vuko, M.; Rodriguez-Canales, J.; Zimmermann, J.; Schick, M.; O’Brien, C.; Paz-Ares, L.; Goldman, J. W.; Garassino, M. C.; Gay, C. M.; more...
    Molecular Cancer (2024)

    Fulltext@MSK | Save
  • Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III/IV ovarian cancer
    Journal Article

    Pignata, S.; Bookman, M.; Sehouli, J.; Miller, A.; Penson, R. T.; Taskiran, C.; Anderson, C.; Hietanen, S.; Myers, T.; Madry, R.; more...
    Gynecologic Oncology (2023)

    Fulltext@MSK | Save
  • High interobserver variability among pathologists using combined positive score to evaluate PD-L1 expression in gastric, gastroesophageal junction, and esophageal adenocarcinoma
    Journal Article

    Robert, M. E.; Ruschoff, J.; Jasani, B.; Graham, R. P.; Badve, S. S.; Rodriguez-Justo, M.; Kodach, L. L.; Srivastava, A.; Wang, H. L.; Tang, L. H.; more...
    Modern Pathology (2023)

    Fulltext@MSK | Save
  • Risk of diabetes mellitus among users of immune checkpoint inhibitors: A population-based cohort study
    Journal Article

    Chan, J. S. K.; Lee, S.; Kong, D.; Lakhani, I.; Ng, K.; Dee, E. C.; Tang, P.; Lee, Y. H. A.; Satti, D. I.; Wong, W. T.; more...
    Cancer Medicine (2023)

    Fulltext@MSK | Save
  • Multi-institutional study of pathologist reading of the programmed cell death ligand-1 combined positive score immunohistochemistry assay for gastric or gastroesophageal junction cancer
    Journal Article

    Fernandez, A. I.; Robbins, C. J.; Gaule, P.; Agostini-Vulaj, D.; Anders, R. A.; Bellizi, A.; Chen, W.; Chen, Z. E.; Gopal, P.; Zhao, L.; more...
    Modern Pathology (2023)

    Fulltext@MSK | Save
  • CD8(+) T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapy
    Journal Article

    Huseni, M. A.; Wang, L.; Klementowicz, J. E.; Yuen, K.; Breart, B.; Orr, C.; Liu, L. F.; Li, Y.; Gupta, V.; Li, C.; more...
    Cell Reports Medicine (2023)

    Fulltext@MSK | Save